![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » RANBAXY JV LAUNCHES ANTI-DIABETES DRUG IN JAPAN
RANBAXY JV LAUNCHES ANTI-DIABETES DRUG IN JAPAN
Nihon Pharmaceuticals Industry (NPI), a joint venture between Ranbaxy Laboratories and Nippon Chemiphar (NC), has launched its first, co-developed product Vogseal 0.2mg & 0.3mg tablets (generic Voglibose) in Japan. According to a release issued by Ranbaxy to the BSE today, the product is used for the treatment of diabetes, and will be made available at medical institutions across the country through a network of wholesalers.
Big News Network (http://feeds.bignewsnetwork.com/redir.php?jid=e1ee9b09d426420a&cat=6dcd932030878143)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct